Conference on Plant-Made Pharmaceuticals
Home Program at a glance Poster presentations Registration Getting there, being there Sponsors Press releases Organization
Version Française
You may access the abstracts by clicking on the presentations' titles.


Program last updated 2003-03-10
The co-hosts of the Conference are plant-factory companies. They will present their platform, product or technology at one of five end-of-morning or end-of-day sessions. See further for details.


Day 0 – Sunday, March 16, 2003



12:00 - 18:00

Registration











12:30

Social activities - Things to do on your own


Just by the hotel, a walk in the snow, on the cliff over the River: Plaines d'Abraham - www.odysseecanada.com

At a walking distance, the European atmosphere of Vieux Québec, the old quarter with its small streets, restaurants, forts, museums, bars and shopping:
Hôtel du Parlement - www.assnat.qc.ca
Quartier Petit Champlain, for exquisite shopping - www.quartier-petit-champlain.qc.ca
Two great museums: Musée du Québec - www.mdq.org and Musée de la Civilisation  - www.mcq.org
Fortifications de Québec, Le Parc de l'Artillerie - www.parkscanada.gc.ca
... and much more

Not too far, by cab:
Hôtel de glace, a real hotel made of ice (with a bar!) - www.icehotel-canada.com
Parc de la Chute Montmorency, a magnificent waterfall, its snow mountain and its restaurant - www.chutemontmorency.qc.ca
Half a mile of indoor shopping in Sainte-Foy - www.placelaurier.com

For more tourism information - www.ville.quebec.qc.ca



18 :00

Welcome Cocktail






Day 1 – Monday, March 17, 2003



07:30

BREAKFAST




08:30

PLENARY

THE CRITICAL NEED FOR PLANT-MADE PHARMACEUTICALS
Opening notes by Mr. Alain Dubuc, Le Soleil, President and Publisher (Biography.pdf)


Three views on the genesis of plant-factories: their scientific roots, how they will serve Society, and their business drivers.

Presented by: / Présenté par : Gouvernement du Québec




08:45

TECHNOLOGY – Plant-factories: An Historical Perspective
Dr. Paul Arnison, FAAR Biotechnology Group (Biography.pdf)
Download the PowerPoint presentation


Plant-made Pharmaceuticals own a lot to the science of Mendel, Watson and Crick, Gilbert, Cohen and Boyer, Genentech, PGS ... This historical perspective will show how plant and genetic sciences converged to plant factories.




09:05

STEWARDSHIP - Saving Lives: Plant-made Pharmaceuticals and the World’s Health System
Dr. Halla Thorsteinsdottir, University of Toronto, Co-author, Top 10 Biotechnologies for Improving Health in Developing Countries (Biography.pdf)


Our world need better production systems for protein drugs, because:
1. the rising complexity, demand and cost of the new generation of protein-based drugs
2. new biologic products, including plant-made edible vaccines will help the poorest of us to access better health
3. the blood supply: AIDS, hepatitis, prions and the Nile Virus: affordable recombinant blood proteins would render the management of blood supply safe, and simpler.



09:25

BUSINESS - The Capacity and Capability “Crunch”: Myth or Reality?
Dr. Brandon Price, Goodwin Biotechnology, Inc., President & CEO (Biography.pdf)


Title: The Capacity and Capability “Crunch”: Myth or Reality?

Presenter: Brandon J. Price, Ph.D.
President & CEO, Goodwin Biotechnology Inc.

Recently, much has been made about the scarcity of manufacturing resources for biopharmaceutical products. While there is general consensus on current and near-future available capacity, there are severely conflicting reports on future demand – and little account has been taken of new product categories such as edible vaccines, prophylactic treatments for chronic conditions, generic biodrugs, and the like. Prospectively, transgenic plants offer many desirable attributes, such as cost, scale and safety, as biomanufacturing systems. However, there are a number of “capability” issues that still need to be addressed with these systems. We will explore both the capacity and capability “crunch” in this session and offer some updated projections for the future.



09:45

Coffee Break




10:00

CONCURRENT SESSIONS (A or B)




A

SCIENCE SYMPOSIA - The Science of Biosafety & Biovigilance
Chair: Ms. Cindy Smith, USDA (Biography.pdf)


Plant-made pharmaceuticals will remain «regulated products», thus being grown under strict containment. Scientists around the world are developing biosafety technologies to insure containment, and biovigilance technologies to confirm it that includes Male Sterility, Gene/Protein Testing, Spatial and Temporal Isolation and other Good Agricultural Procedures (GAP).






Making Plants for Medicine: Production, Containment and Non-target Impacts of a Tobacco based System for Making Recombinant Proteins
Dr. Rima Menassa, Agriculture and AgriFood Canada (Biography.pdf)






Pollen Coat Targeting Technology: A Strategy for the Prevetion of Pollen-mediated Outcrossing
Dr. Liz Foster, Agriculture and Agri-Food Canada, Research Scientist (Biography.pdf)






GMO:COIS: Genetically Modified Organisms – Copyright Owner Identification System
Dr. Hubert Bernauer, ATG - Biosynthetics GmbH (Biography.pdf)
Download the PowerPoint presentation





B

PLATFORM PRESENTATIONS
Chair: Mr. Jeffrey L. Taylor, Barnes & Thornburg, Chairman - Federal Relations (Biography.pdf)


Presented by: / Présenté par :



Speed, Containment and Cost Advantages of Therapeutic Protein Production in the Lemna System™
Dr. David G. Spencer, Biolex (Biography.pdf)






The Moss Bioreactor: Creating a Green Animal for Safe Cost-effective Production of Biopharmaceuticals
Dr. Sabrina Wagner, greenovation Biotech GmbH (Biography.pdf)






Developing Plant Growth Facilities for Plant-Based Research and Production
Mr. Steven Kroft, Conviron (Biography.pdf)






Taking Pharmaceutical Production Underground
Mr. Brent H. Zettl, B.S.A., Prairie Plant Systems, Inc. / SubTerra LLC (Biography.pdf)








Bio-Containment Regulations in the US and Canada
M. Richard Denis, Agritechnove, Inc. (Biography.pdf)





12:00

Lunch, traditional Sugar Shack style

Posters and exhibits

Presented by: / Présenté par :




14:00

CONCURRENT SESSIONS (A or B)




A

STEWARDSHIP & REGULATORY - Stringent Containment and Biomass Production Regulations
Chair: Ms. Rachel Lattimore, Arents/Fox (Biography.pdf)


New regulations and guidelines are being developed for the testing and growth of plant-factories in the field.  These will be discussed, with input from US and Canadian regulators, as well from industry representatives from both large and small technology providers.

Presented by: / Présenté par :





Current Permit Procedures in the USA
Dr. Margaret Jones, USDA, Biotechnologist (Biography.pdf)
Download the PowerPoint presentation






Forward-looking Notes from the Canadian Regulator
Dr. Stephen Yarrow, Director, Plant Biosafety Office, Canadian Food Inspection Agency





How the Industry Complies with the Regulations in the USA
Mr. Phil Eppard, Monsanto Protein Technologies, Regulatory Affairs Lead (Biography.pdf)






How the Industry Complies with the Regulations in Canada
Mr. Rich Keon, SemBioSys Genetics, Inc., Manager, Planting Operations and Field Regulatory Affairs (Biography.pdf)





B

SCIENCE SYMPOSIA - Post-translational Processing & Protein Trafficking
Chair: Dr. Loïc Faye, CNRS Rouen (Biography.pdf)


Can plant-factories produce humano-compatible glycosylation? Several promising strategies will be presented by scientists from the leading laboratories on plant post-translational modifications.

Presented by: / Présenté par :





From Glycobiology to Glycoengineering
Dr. Véronique Gomord, CNRS-Université de Rouen (Biography.pdf)






The Effect of Glycosylation on the Pharmacology of Therapeutic Monoclonal Antibodies Made in Corn Seed
Dr. Jonathan McIntyre, Monsanto Protein Technologies, Chief Scientist (Biography.pdf)






Modifying Glycosylation Patterns in Moss
Dr. Sabrina Wagner, greenovation Biotech GmbH, CEO (Biography.pdf)
Download the PowerPoint presentation






Towards Human-Type N-Linked Glycans in Plants
Dr. Ir. Dion E.A. Florack, Cell Cybernetics, Plant Research International B.V. (Biography.pdf)
Download the PowerPoint presentation





15:30

Coffee Break




15:45

CONCURRENT SESSIONS (A or B)




A

SCIENCE SYMPOSIA - New Plant Transformation & Expression Systems - Part 1
Chair: Dr. Maurice M. Moloney, SemBioSys Genetics, Inc., Chief Scientific Officer (Biography.pdf)


The capacity to transform the genome of plants is not an issue of "if", but of "how". This session will present the most recent advances in transformation and expression tools to gain better control of proteolysis and silencing, to have the proteins secreted, to transform the chloroplasts and other recent scientific achievements. Two sessions will be dedicated to these topics.






Control of Proteolysis in Plant Systems
Dr. Dominique Michaud, Université Laval (Biography.pdf)






Unique Targeting Results in Maize
Dr. Kan Wang, Iowa State University (Biography.pdf)








Chloroplast for Expression of Recombinant Proteins
Dr. Pal Maliga, Rutgers University (Biography.pdf)






Genoplasty - using modified oligonucleotides for genome targeting
Dr. Peter Beetham, Cibus Genetics, LLC, Vice President, Research (Biography.pdf)





B

PLATFORM PRESENTATIONS
Chair: Dr. Tony Jevnikar, Plantigen (Biography.pdf)


Presented by: / Présenté par :



Using Humanized Proteins from Transgenic Plants for Preventing and Treating Autoimmune Diseases
Dr. Tony Jevnikar, Plantigen (Biography.pdf)






Biopharma at Syngenta – Building on Strengths, Building Strong Partnerships
Dr. Antony Blanc, Syngenta (Biography.pdf)
Download the PowerPoint presentation






Human Health Products Produced from Transgenic plants
Dr. John Howard, ProdiGene (Biography.pdf)






Multiparameter Software Algorithm Supporting Rational Gene Design for High Yield, Plant based Protein Expression
Dr. Michael Liss, Geneart GmbH (Biography.pdf)





18:00

End of afternoon sessions






Day 2 – Tuesday, March 18, 2003



07:30

BREAKFAST




08:30

PLENARY

CURRENT CHALLENGES AND SOLUTIONS
Opening notes: Mr. Patrick le Morvan, Novartis and Drug Information Association and Ms. Carole Nap, BioteCanada (Biography.pdf)


PMPs, as of now. The way people see them, their business models, and what their toolbox holds and is missing.



08:45

STEWARDSHIP - What Do People Want, and Want to Know?
Mr. Justin Gillis, Washington Post (Biography.pdf)


Plant-made pharmaceuticals promise better, cheaper drugs produced from a green, natural and renewable source which resonates well with the general public. However, as all new technologies, PMP's raise their lot of concerns.
This session will offer a personal view on the public opinion after the Prodigene incident and before the launch of the first plant-made pharmaceutical.



09:05

BUSINESS - The Business Case for Plant-factories
Dr. Ulrich Steiner, Bayer (Biography.pdf)
Download the PowerPoint presentation


From R&D outfits pushing a promising technologies, Plant-factories are now stand-alone companies and business units of large agbio companies, working with biopharma and industrial partners.
This presentation will show how they will make money from partnerships, contract manufacturing and product development.



09:25

TECHNOLOGY - Achievements & Current Challenges
Dr. Roger Wyse, Burrill & Company (Biography.pdf)


Technology is one of the main drivers of emerging industrial sectors such as plant-factories. Technology provides speed and capacity, it delivers compliance to quality and regulatory standards, it generates lower costs and strategic advantages .... and it creates financial value.
The presentation will show which achievements of plant-made pharmaceuticals bear the most value, and what technological issues the players in this space must address to fulfill their promises of riches.
Our guide will be one of the very few persons who saw in great details the technological toolbox of all the plant-made pharmaceuticals companies.



09:45

Coffee Break




10:00

CONCURRENT SESSIONS (A or B)




A

STEWARDSHIP & REGULATORY - Clinical Development: Regulatory Issues for Plant-factories
Chair: Dr. Scott A. Oglesby, Drug Development, Worldwide Regulatory Affairs, Parexel (Biography.pdf)
Download the PowerPoint presentation


The regulators tend to consider plant-made pharmaceuticals like other biologic drugs. This presentation will show how the rules are applied and modified to approve the products from plant-factories. Representatives from the regulatory authorities and experts from the industry will discuss current clinical trials of plant-made drugs.

Presented by: / Présenté par :





The FDA/USDA Guidance for Industry on Biologics Made in Plants-history and Highlights
Dr. Kathryn E. Stein, MacroGenics, Inc., Vice President, Product Development and Regulatory Affairs (Biography.pdf)






Forward Looking Notes
Dr. Elwyn Griffiths, Health Canada, Associate General Director (Biography.pdf)






Gastric Lipase Phase II
Mr. Pierre Dorfmann,M.D., Meristem, phase II, Gastric lipase (Biography.pdf)






Patient Specific Vaccine Therapy for Non-Hodgkin's Lymphoma: A Succesful Phase 1 Clinical Trial of a Plant Made Biologic
Dr. Barry Holtz, LSBC (Biography.pdf)





B

PLATFORM PRESENTATIONS
Chair: Dr. Bernard Coupal, T2C2 (Biography.pdf)


Presented by: / Présenté par :



Pollen-Mediated Gene Flow in Maize
Dr. Xavier Delannay, Monsanto Protein Technologies (Biography.pdf)






Mini-Chromosomes for Genetic Modification of Crops
Dr. Mich Hein, CEO, Chromatin, Inc. (Biography.pdf)






ExpressTec™
Mr. Scott Deeter, Ventria Bioscience (Biography.pdf)






Novel Platforms for Protein Production in Plants
Dr. Yuri Gleba, CEO, Icon Genetics AG (Biography.pdf)






Plant-Made Antibodies
Mr. Elliott Fineman, Planet Biotechnology Inc. (Biography.pdf)





12:00

Lunch “Around the apple”

Posters and exhibits

Presented by: / Présenté par :




14:00

CONCURRENT SESSIONS (A or B)




A

SCIENCE SYMPOSIA - Compliance, Validation and Downstream Processing
Chair: Dr. Barry Holtz, LSBC (Biography.pdf)


Presented by: / Présenté par :





The Science of Downstream Processing
Dr. Barry Holtz, LSBC (Biography.pdf)






More on the Science of Downstream Processing
Dr. Jeanne Novak, Colorado BioReg / CBR International, Owner/Principal Consultant (Biography.pdf)






Process & Design: Biopharmaceutical Protein Production Utilising Transgenic Tobacco
Dr. David Williams, CropTech Corporation (Biography.pdf)






Dr. Dominique Mison (Meristem Therapeutics), and Dr. Tom Gelineau (SigmaAldrich), will join the presenters for the panel discussion, and to take questions from the room
Dr. Dominique Mison and Dr. Tom Gelineau




B

BUSINESS CASES - Fuel for the Whole Journey: News From the Financial Community
Chair: Dr. Francis Bellido, Société générale de financement (Biography.pdf)


Plant-factory companies lead a double life. They are technology companies that must demonstrate their capacity to deliver products to market ; they are dependent to products with long development cycles. This means patient and clever money, a resource that appears to be scarce these days.
Financial experts will discuss where and how the existing and emerging plant-made pharmaceuticals vehicles will find money in the private or public markets, and elsewhere. As investors, our experts will also present their own strategies for profit in these uncertain times.





Dr. Håkan Telenius, MDS Capital Corporation, Senior Investment Analyst (Biography.pdf)







Dr. Roger Wyse, Burrill & Company, Managing Director (Biography.pdf)







Dr. Thomas L. Steen, Cybus Capital




15:30

Coffee Break




15:45

CONCURRENT SESSIONS (A or B)




A

SCIENCE SYMPOSIA - New Plant Transformation & Expression Systems - Part 2
Chair: Dr. Elizabeth Hood (Biography.pdf)


The capacity to transform the genome of plants is not an issue of "if", but of "how". This session will present the most recent advances in transformation and expression tools to gain better control of proteolysis and silencing, to have the proteins secreted, to transform the chloroplasts and other recent scientific achievements. Two sessions will be dedicated to these topics.






Expression of Human Antibodies in Eukaryotic Algae
Dr. Steven Mayfield, The Scripps Research Institute (Biography.pdf)








Plant Virus Particle-Based Candidate Vaccine Against Respiratory Syncytial Virus
Dr. Vidadi Yusibov, AIMV Fraunhofer (Biography.pdf)






Enhancing Transgenic Plant Products Through Direct Molecular Evolution
Dr. David McElroy, Verdia, Inc. (Biography.pdf)








TraitMill TM : An applied genomics platform for the improvement of cereals
Dr. Yves Hatzfeld, CropDesign (Biography.pdf)





B

PLATFORM PRESENTATIONS
Chair: Dr. Chantal Brunet, Innovatech Québec (Biography.pdf)


Presented by: / Présenté par :



Developing an integrated product development system
Ms. Nathalie Landry, Medicago (Biography.pdf)
Download the PowerPoint presentation






Perspectives on an Emerging Antibody Pipeline
Dr. Michael Pauly, Epicyte Pharmaceuticals, Inc. (Biography.pdf)






Chloroplast Derived Vaccines and Biopharmaceuticals
Dr. Henry Daniell, Chlorogen (Biography.pdf)






From Screening to Large Scale Production of Biopharmaceutical Proteins in Recombinant Plant Systems
Dr. Manfred Theisen, Meristem Therapeutics (Biography.pdf)





18:00

End of afternoon sessions




18:30

BANQUET

Featuring: The Famous Famille Painchaud and the Biosafeties (formerly known as The Biohazards)
A rock band in vivo (live) on stage!





Day 3 – Wednesday, March 19, 2003



07:30

BREAKFAST




08:30

PLENARY

A BRIGHT FUTURE: THE ROAD TO MARKET
Chair: Dr. Kathryn Howard, Industry Canada, Director General, Life Sciences Branch (Biography.pdf)
Download the PowerPoint presentation


The future of plant-made pharmaceuticals in the eyes a pharma executive, a politician and a former CEO of a plant-factory company

Presented by: / Présenté par : Industry Canada




08:45

BUSINESS - Protein Production in the Future of Biopharma
Dr. Richard McCloskey, Centocor (Biography.pdf)


Production of antibodies and antibody fragments, as well as other important pharmaceutical proteins in transgenic plants can be a powerhouse production toolbox. This industry needs to produce more data for more potential products in more systems to compete with the vigorous efforts to lower the cost of goods in mammalian production systems. The major drivers are cost, cost ,and cost. Producing transformational products for human application will be useless if the patients cannot afford them and governments refuse to pay for them. Data are needed, in addition to that mentioned for; 1) more and better data about downstream purification, 2) some evaluation of the potential for adverse immune responses in humans to plant glycoforms, and comparison of that “immunogenicity” to mammalian products, 3) useful comparative costs for facility creation, 4) when aseptic procedures enter the production stream, 5) regulatory processes and postures now and in the future.



09:05

STEWARDSHIP - Prescription for Health, Environmental and Industrial Benefits
The Honourable Yves Morin, Member of the Senate, Government of Canada Download the PowerPoint presentation


The Government of Canada is committed to an ambitious Innovation Strategy, and recognizes that biotechnology and plant-made pharmaceuticals have a key role to play in making Canada a world leader in scientific research and development. At the same time, the Government’s first priority remains protecting the health and safety of Canadians, their food supply, the environment, and animals. This presentation will examine what steps the Government is taking to both foster innovation and ensure that its regulatory framework continues to achieve its health and safety objectives, as our society moves toward the biotech-based economy.



09:25

TECHNOLOGY - The Years to Come: Promises of PMP’s
Mr. François Arcand, Conference on Plant-Made Pharmaceuticals (Biography.pdf)


The Years to Come: Promises of PMP’s

An inventory of the promises of plant-factory companies CEOs. What they will deliver, how, when. This forward looking speech considers the future of Plant-made Pharmaceutical (PMPs) according to three angles : regulatory/stewardship, business and products. It is drawn for the vision of several leaders in the field, and publicly announced projects. Possible evolution of the regulatory context from field trials to larger-scale production will be explored. Several business models and their expected financing will be discussed. But the core of the presentation will illustrate what PMPs are in the pipeline of companies and research organizations,

arcandf@cpmp2003.org



09:45

Coffee Break




10:00

CONCURRENT SESSIONS (A or B)




A

SCIENCE SYMPOSIA - Multi-ton Production of Recombinant Proteins
Chair: Dr. Steve Howell, Iowa University (Biography.pdf)
Download the PowerPoint presentation


Plant-factories demonstrated their capability to produce complex proteins, but they also promise to deliver biologics in quantities unimaginable under the current, cell-lines systems. This science symposia will present the science behind the ultra-large scale production and processing of transgenic biomass.


Presented by: / Présenté par :





Somatic Embryogenesis as a Production System
Dr. Wolfgang Schuch, CellFor (Biography.pdf)






Scale-up and Industrial Production of Recombinant Therapeutic Proteins Expressed in Corn
Dr. Dominique Mison, Meristem Therapeutics (Biography.pdf)






Large Scale Production of Alfalfa Biomass and its Processing by Wet Fractionnation
Ms. Michèle Martel, Medicago (Biography.pdf)
Download the PowerPoint presentation





B

PLATFORM PRESENTATIONS
Chair: Dr. Charles Arntzen, Arizona State University (Biography.pdf)


Presented by: / Présenté par :



Efficient Protein Purification Using Plant Oilbody Technology
Dr. Ronald Bassuner, Head, Pilot Manufacturing and Process Development, SemBioSys Genetics (Biography.pdf)






A Production Enhancement and Isolation System for Plant-made Pharmaceuticals
Dr. Peter Mascia, Ceres Inc. (Biography.pdf)






Edible Vaccines
Dr. Charles Arntzen, Arizona State University (Biography.pdf)






Serological Response Following Oral Administration of a Plant-Made Antigen
Dr. Steven R. Webb, Dow AgroSciences, Project Success Leader (Biography.pdf)








Unique Applications for Transgenic Tobacco: The Large Scale Production of Apoptosis-Inducing Proteins in Tobacco
Dr. David Williams, Senior VP and Chief Technology Officer, CropTech Corporation (Biography.pdf)





12:00

Lunch, great cheeses from Québec

Posters and exhibits

Presented by: / Présenté par :




14:00

CONCURRENT SESSIONS (A or B)




A

BUSINESS CASES - Biopharmaceuticals in Plants: A Business Justification
Chair: Dr. Julio Baez, FibroGen, Senior Research Fellow (Biography.pdf)


This session will explore the justification for different types of companies such as Large-size pharmaceutical (Centocor/J&J), Large-size biotechnology (Amgen), Small-size biotechnology (NeoRx), and Chemical (Sigma) to get involved with companies producing pharmaceuticals from plants. The leaders from these companies responsible for collaborative programs on Plant Made Pharmaceuticals (PMPs) will discuss from their perspectives the justification to get into research and production relationships with companies producing pharmaceuticals from plants. Also they will discuss how PMPs are integrated into the research and commercialization strategies in their respective companies.

Presented by:/Présenté par : Société générale de financement





The Decision to Develop PMP's - a Small Company's Perspective
Ms. Becky J. Bottino, NeoRx, Sr. Vice President, Technical Operations (Biography.pdf)






What a Biotech Company Wants from a Plant Antibody Company
Dr. Richard McCloskey, Centocor/J&J, Vice President Medical Research (Biography.pdf)






Coming to Grips with Transgenics: Deciding Where to Focus
Dr. Jeff Yant, Amgen, Scientist (Biography.pdf)






Present and Future Capacity for the Isolation and Purification of Plant-Made-Pharmaceuticals
Mr. Tom Gelineau, Sigma, Director of U.S. Sales (Biography.pdf)





B

STEWARDSHIP & REGULATORY - No Man’s an Island: Voices of the Stakeholders
Chair: Mr. Ron Doering, Gowlings (Biography.pdf)


Hopes, concerns: from consumers to farmers, from patients to food producers, opinions vary on plant-made pharmaceuticals. Let’s hear them on the challenges and promises of plant-factories.




A Bioethicist's View
Mr. David Castle, University of Guelph, Department of Philosophy, Co-author, Top 10 Biotechnologies for Improving Health in Developing Countries (Biography.pdf)






The Pew Initiative and “Pharming the Field”
Dr. Mike Fernandez, Director of Science, PEW Initiative on Food and Biotechnology (Biography.pdf)






A Patient's View
Ms. Virginia Ladd, President, American Autoimmune Related Diseases Association (AARDA) (Biography.pdf)
Download the PowerPoint presentation








The Farm Perspective
Mr. Arden Schneckenburger, AgExcell, President (Biography.pdf)






From the Food Industry
Dr. Jeff Barach, National Food Processors Association, Vice President Special Projects (Biography.pdf)





15:30

Coffee Break




15:45

SCIENCE SYMPOSIA - Genomics, Proteomics and Metabolomics
Chair: Dr. Bill Crosby, University of Saskatchewan (Biography.pdf)


Top-genomic science as viewed from plant-factory companies.






Exploiting Plant Genomic Information to Predict and Test Protein Functions and Activities
Dr. Christian Hardtke, University McGill, Professor of Biology (Biography.pdf)






N-Glycan Profiling of Plant Proteins
Dr. Patrice Lerouge, Université de Rouen, Professor in Biochemistry (Biography.pdf)








Advanced MS-Applications for Protein Profiling
Dr. Yves Leblanc, Sciex Corporationn Download the PowerPoint presentation








Process Proteomics: The Uses of ProteinChip™ Technology for Rapid Expression Monitoring and Purification Development of Biopharmaceuticals
Mr. Paul Smith, Ciphergen Biosystems (Biography.pdf)





18:00

End of conference